+590.4%
GS vs MRNA
+561.6%
+28.8%
-45.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.1% | -2.2% | +2.3% | +0.1% |
| 7D | +0.9% | +5.5% | -4.5% | +0.8% |
| 30D | -1.6% | +158.7% | -160.3% | -6.9% |
| 3M | -4.5% | +182.1% | -186.6% | -10.3% |
| 6M | +20.9% | +151.8% | -130.9% | +14.0% |
| YTD | +19.9% | +393.6% | -373.7% | +8.7% |
| 1Y | +41.4% | +499.5% | -458.1% | +26.6% |
| 3Y | +239.2% | +29.3% | +209.9% | +218.0% |
| 5Y | +185.0% | -65.1% | +250.1% | +165.9% |
| All | +590.4% | +561.6% | +28.8% | +547.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling